Systemic Lupus Erythematosus
LymphoStat-B shown to be safe, well-tolerated in patients with systemic lupus erythematosus
Published in Drug Week, November 11th, 2005
Human Genome Sciences, Inc., (HGSI) announced that the results of a phase II clinical trial demonstrated that LymphoStat-B (belimumab) was safe, well-tolerated, and showed signs of clinical effect in patients with systemic lupus erythematosus (SLE or lupus), although the drug did not meet the overall primary efficacy endpoints of reducing the signs and symptoms of SLE at week 24 as measured by SELENA SLEDAI 1-2, or increasing the time to first SLE flare over 52 weeks.
LymphoStat-B reduced the signs and symptoms of SLE at week 52 at a level of statistical significance in seropositive patients, a subgroup that represented 75% of the study's patient population, as measured...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2005-11-11)
More Articles from Drug Week
- Breast Cancer
Curcumin halts spread of breast cancer in mice - Cancer Therapy
Median survival improved by more than half in phase III metastatic melanoma trial of Oncophage - Drug Development
Phase II trial initiated for Cand5 in wet age-related macular degeneration - Renal Cell Carcinoma
Preliminary data shows renal cancer drug is safe and well tolerated - Addiction Medicine
Beta-carbolines block opiate withdrawal - Adjuvant Chemotherapy
Colorectal cancer adjuvant treatment in elderly patients discussed - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
